· News · News Desk
openFDA shows 43 semaglutide and 21 tirzepatide recalls — overwhelmingly from compounders. Payless, New Life Pharma (Nomida), ProRx, GenoGenix, Aequita, and the Chinese API supplier Harbin Jixianglong Biotech, with sterility and CGMP failures dominating.
This brief is part of the Novusyn Research news desk. We track peptide clinical readouts, regulatory actions, and pharma developments in neutral, evidence-led language for scientifically literate readers.
For related context, see the full news desk, clinical trials tracker, regulation tracker, compound directory, and guides library.